Results 1 to 10 of about 142,747 (120)

How CAR T Cells Breathe

Cells, 2022
The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism.
Christopher Forcados, Sandy Joaquina, Nicholas Paul Casey, Benjamin Caulier, Sébastien Wälchli   +4 more
doaj   +1 more source

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function

Frontiers in Immunology, 2022
The quality of chimeric antigen receptor (CAR)-T cell products, namely, memory and exhaustion markers, affects the long-term functionality of CAR-T cells.
Masaya Suematsu, Shigeki Yagyu, Nobuyoshi Nagao, Susumu Kubota, Yuto Shimizu, Miyuki Tanaka, Yozo Nakazawa, Toshihiko Imamura   +7 more
doaj   +1 more source

Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway

Oncogenesis, 2021
Pancreatic carcinoma (PC) is one of the most common malignancies. Chimeric antigen receptor (CAR)-modified T cells has achieved remarkable efficacy in the treatment of hematological malignancies.
Yaoxin Gao, Haizhen Lin, Dandan Guo, Sijia Cheng, Ying Zhou, Li Zhang, Jie Yao, Muhammad Asad Farooq, Iqra Ajmal, Yixin Duan, Cong He, Lei Tao, Shijia Wu, Mingyao Liu, Wenzheng Jiang   +14 more
doaj   +1 more source

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells

Advanced Science, 2023
The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL) blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy for T‐ALL. However, CD38 expression in normal T/NK cells causes fratricide
Chan Liao, Yajie Wang, Yanjie Huang, Yanting Duan, Yan Liang, Jiangqing Chen, Jie Jiang, Kai Shang, Chun Zhou, Ying Gu, Nan Liu, Xun Zeng, Xiaofei Gao, Yongmin Tang, Jie Sun   +14 more
doaj   +1 more source

TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss

Cancer Cell International, 2021
Background To investigate the effect of TriBAFF-CAR-T cells on hematological tumor cells. Methods TriBAFF-CAR-T and CD19-CAR-T cells were co-cultured with BAFFR-bearing B-cell malignancies at different effector/target ratios to evaluate the anti-tumor ...
Guangchao Li, Qing Zhang, Zhi Liu, Huijuan Shen, Yangmin Zhu, Zhao Zhou, Wen Ding, Siqi Han, Jie Zhou, Ruiming Ou, Min Luo, Shuang Liu   +11 more
doaj   +1 more source

Impact of Manufacturing Procedures on CAR T Cell Functionality

Frontiers in Immunology, 2022
The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in the past few decades. As of today, there are six CAR T cell products that have been approved by the FDA: KYMRIAH (tisagenlecleucel, CD19 CAR T cells), YESCARTA ...
Norihiro Watanabe, Feiyan Mo, Feiyan Mo, Mary Kathryn McKenna   +3 more
doaj   +1 more source

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

Journal of Hematology & Oncology, 2019
The current treatment for pediatric acute lymphoblastic leukemia (ALL) is highly successful with high cure rate. However, the treatment of adult ALL remains a challenge, particularly for refractory and/or relapsed (R/R) ALL.
Juanjuan Zhao, Yongping Song, Delong Liu
doaj   +1 more source

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV

Frontiers in Immunology, 2019
Re-directing T cells via chimeric antigen receptors (CARs) was first tested in HIV-infected individuals with limited success, but these pioneering studies laid the groundwork for the clinically successful CD19 CARs that were recently FDA approved.
Gloria B. Kim, Kristen Hege, James L. Riley   +2 more
doaj   +1 more source

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells

Frontiers in Immunology, 2023
Chimeric antigen receptors (CARs) in the canonical “second generation” format provide two signals for inducing T cell effector functions; the primary “signal-1” is provided through the TCR CD3ζ chain and the “signal-2” through a linked costimulatory ...
Simone Thomas, Simone Thomas, Hinrich Abken, Hinrich Abken   +3 more
doaj   +1 more source

Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings

ImmunoInformatics, 2023
Chimeric antigen receptor (CAR) T-cell based immunotherapy has shown its potential in treating blood cancers, and its application to solid tumors is currently being extensively investigated.
Runpeng Li, Prativa Sahoo, Dongrui Wang, Qixuan Wang, Christine E. Brown, Russell C. Rockne, Heyrim Cho   +6 more
doaj   +1 more source